{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:00:08Z","timestamp":1787169608133,"version":"build-2736575974"},"reference-count":32,"publisher":"BMJ","issue":"1","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child"],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Since 1997, strong incentives have been introduced worldwide to improve access to safe and effective medicines addressing the therapeutic needs of children. ACE inhibitors, the most prescribed antihypertensive drugs in the paediatric population, are one of the prototype drugs targeted by the legislation initiatives. Our purpose in assembling this review is to evaluate and describe the current evidence for the efficacy and safety profile of ACE inhibitors in the paediatric population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The authors made a descriptive review of the literature from 1980 to 2015 using the following search terms: hypertension, child, paediatric, ACE (inhibitors), renin\u2013angiotensin aldosterone system, captopril, lisinopril, enalapril, ramipril and fosinopril.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 16 studies evaluating efficacy and safety of ACE inhibitors were included in this review. The included studies demonstrate that ACE inhibitors have the potency to decrease the systolic and\/or diastolic blood pressure with an overall favourable safety profile in a short-term period. More importantly, the incentives resulted in an improvement of the overall availability of paediatric labelling, dosing and safety information for ACE inhibitors. However, they failed to fulfil several of paediatric needs: absence of long-term safety data on growth and maturation, absence of commercially available child-friendly formulations and incomplete evaluation of the entire paediatric hypertension population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Additional efforts are needed to close the gap between the availability of drugs that are labelled and indicated for paediatric use and the actual drug usage in children, especially in young children, neonates and children with severe hypertension, renal transplantation or severe renal impairment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/archdischild-2016-310582","type":"journal-article","created":{"date-parts":[[2016,9,28]],"date-time":"2016-09-28T22:59:29Z","timestamp":1475103569000},"page":"63-71","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":27,"title":["Therapeutic efficacy and safety of ACE inhibitors in the hypertensive paediatric population: a review"],"prefix":"10.1136","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2660-7460","authenticated-orcid":false,"given":"Evelien","family":"Snauwaert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vande Walle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"De Bruyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2016,9,28]]},"reference":[{"issue":"(Suppl 4th Report)","key":"key-10.1136\/archdischild-2016-310582-1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1542\/peds.114.2.S2.555","article-title":"The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents","volume":"114","author":"National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents","year":"2004","journal-title":"Pediatrics"},{"key":"key-10.1136\/archdischild-2016-310582-2","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s40292-015-0114-3","article-title":"Hypertension in young people: epidemiology, diagnostic assessment and therapeutic approach","volume":"22","author":"Battistoni","year":"2015","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"key-10.1136\/archdischild-2016-310582-3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jpeds.2015.04.016","article-title":"Hypertension prevalence, cardiac complications, and antihypertensive medication use in children","volume":"167","author":"Dobson","year":"2015","journal-title":"J Pediatr"},{"key":"key-10.1136\/archdischild-2016-310582-4","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1161\/01.CIR.97.14.1411","article-title":"Angiotensin-converting enzyme inhibitors","volume":"97","author":"Brown","year":"1998","journal-title":"Circulation"},{"key":"key-10.1136\/archdischild-2016-310582-5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s00228-007-0390-5","article-title":"Paediatric clinical pharmacology: at the beginning of a new era","volume":"64","author":"Hoppu","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"key-10.1136\/archdischild-2016-310582-6","first-page":"CD008117","article-title":"Pharmacological interventions for hypertension in children","volume":"2","author":"Chaturvedi","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.1136\/archdischild-2016-310582-7","unstructured":"Wells GA , Shea B , O'Connell D , et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Secondary The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses, 2011. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp"},{"key":"key-10.1136\/archdischild-2016-310582-8","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"key-10.1136\/archdischild-2016-310582-9","first-page":"A207","article-title":"Treatment of neonatal hypertension with captopril","volume":"20","author":"Odea","year":"1986","journal-title":"Pediatr Res"},{"key":"key-10.1136\/archdischild-2016-310582-10","first-page":"829","article-title":"Antihypertensive drug-therapy with captopril in children and adolescents","volume":"8","author":"Sinaiko","year":"1986","journal-title":"Clin Exp Hypertens A"},{"key":"key-10.1136\/archdischild-2016-310582-11","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/S0022-3476(83)80490-9","article-title":"Antihypertensive effect and elimination kinetics of captopril in hypertensive children with renal disease","volume":"103","author":"Sinaiko","year":"1983","journal-title":"J Pediatr"},{"key":"key-10.1136\/archdischild-2016-310582-12","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1542\/peds.75.6.1091","article-title":"Efficacy and safety of captopril in the treatment of severe childhood hypertension: report of the international collaborative study group","volume":"75","author":"Mirkin","year":"1985","journal-title":"Pediatrics"},{"key":"key-10.1136\/archdischild-2016-310582-13","first-page":"841","article-title":"Long term therapy by captopril in children with renal hypertension","volume":"8","author":"Bouissou","year":"1986","journal-title":"Clin Exp Hypertens A"},{"key":"key-10.1136\/archdischild-2016-310582-14","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0022-3476(88)83213-X","article-title":"Renal failure in sick hypertensive premature infants receiving captopril therapy","volume":"112","author":"Tack","year":"1988","journal-title":"J Pediatr"},{"key":"key-10.1136\/archdischild-2016-310582-15","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S0895-7061(03)00900-2","article-title":"A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension","volume":"16","author":"Soffer","year":"2003","journal-title":"Am J Hypertens"},{"key":"key-10.1136\/archdischild-2016-310582-16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3317\/jraas.2007.004","article-title":"Lisinopril in paediatric medicine: a retrospective chart review of long-term treatment in children","volume":"8","author":"Raes","year":"2007","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"key-10.1136\/archdischild-2016-310582-17","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1177\/009127002401102786","article-title":"A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension","volume":"42","author":"Wells","year":"2002","journal-title":"J Clin Pharmacol"},{"key":"key-10.1136\/archdischild-2016-310582-18","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1097\/HJH.0b013e32834c625c","article-title":"Efficacy and safety of valsartan compared to enalapril in hypertensive children: a 12-week, randomized, double-blind, parallel-group study","volume":"29","author":"Schaefer","year":"2011","journal-title":"J Hypertens"},{"key":"key-10.1136\/archdischild-2016-310582-19","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/01.HYP.0000138069.68413.f0","article-title":"Is the extrapolated adult dose of fosinopril safe and effective in treating hypertensive children?","volume":"44","author":"Li","year":"2004","journal-title":"Hypertension"},{"key":"key-10.1136\/archdischild-2016-310582-20","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ahj.2005.12.025","article-title":"Racial differences are seen in blood pressure response to fosinopril in hypertensive children","volume":"152","author":"Menon","year":"2006","journal-title":"Am Heart J"},{"key":"key-10.1136\/archdischild-2016-310582-21","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s004670000422","article-title":"Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension","volume":"15","author":"Soergel","year":"2000","journal-title":"Pediatr Nephrol"},{"key":"key-10.1136\/archdischild-2016-310582-22","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/j.1523-1755.2004.00802.x","article-title":"Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure","volume":"66","author":"W\u00fchl","year":"2004","journal-title":"Kidney Int"},{"key":"key-10.1136\/archdischild-2016-310582-23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cpt.127","article-title":"Pharmacokinetics, pharmacodynamics, and safety of lisinopril in pediatric kidney transplant patients: implications for starting dose selection","volume":"98","author":"Trachtman","year":"2015","journal-title":"Clin Pharmacol Ther"},{"key":"key-10.1136\/archdischild-2016-310582-24","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJMoa0902066","article-title":"Strict blood-pressure control and progression of renal failure in children","volume":"361","author":"W\u00fchl","year":"2009","journal-title":"N Engl J Med"},{"issue":"1","key":"key-10.1136\/archdischild-2016-310582-25","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.amjhyper.2004.01.008","article-title":"Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases","volume":"17","author":"Seeman","year":"2004","journal-title":"Am J Hypertens"},{"key":"key-10.1136\/archdischild-2016-310582-26","first-page":"847","article-title":"Long-term treatment with captopril in pediatric patients with severe hypertension and chronic renal failure","volume":"8","author":"Callis","year":"1986","journal-title":"Clin Exp Hypertens A"},{"key":"key-10.1136\/archdischild-2016-310582-27","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3109\/10641963.2015.1026040","article-title":"A prospective study of frequency and characteristics of cough during ACE inhibitor treatment","volume":"37","author":"Sato","year":"2015","journal-title":"Clin Exp Hypertens"},{"key":"key-10.1136\/archdischild-2016-310582-28","unstructured":"New Pediatric Drug Information Database. Secondary New Pediatric Drug Information Database, 2015. http:\/\/www.accessdata.fda.gov\/scripts\/sda\/sdNavigation.cfm?filter=lisinopril&sortColumn=1d&sd=labelingdatabase&page=1"},{"key":"key-10.1136\/archdischild-2016-310582-29","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1111\/j.1751-7176.2012.00656.x","article-title":"Antihypertensive drug use by children: are the drugs labeled and indicated?","volume":"14","author":"Welch","year":"2012","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"key-10.1136\/archdischild-2016-310582-30","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1542\/peds.2013-2987","article-title":"Impact of pediatric exclusivity on drug labeling and demonstrations of efficacy","volume":"134","author":"Wharton","year":"2014","journal-title":"Pediatrics"},{"key":"key-10.1136\/archdischild-2016-310582-31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00246-013-0813-2","article-title":"Angiotensin-converting enzyme inhibitor nephrotoxicity in neonates with cardiac disease","volume":"35","author":"Lindle","year":"2014","journal-title":"Pediatr Cardiol"},{"key":"key-10.1136\/archdischild-2016-310582-32","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00467-013-2749-4","article-title":"Fetal renin-angiotensin-system blockade syndrome: renal lesions","volume":"29","author":"Plazanet","year":"2014","journal-title":"Pediatr Nephrol"}],"container-title":["Archives of Disease in Childhood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2016-310582","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,9]],"date-time":"2022-07-09T06:45:51Z","timestamp":1657349151000},"score":1,"resource":{"primary":{"URL":"https:\/\/adc.bmj.com\/lookup\/doi\/10.1136\/archdischild-2016-310582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,28]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,14]]},"published-print":{"date-parts":[[2017,1]]}},"alternative-id":["10.1136\/archdischild-2016-310582"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2016-310582","relation":{},"ISSN":["0003-9888","1468-2044"],"issn-type":[{"value":"0003-9888","type":"print"},{"value":"1468-2044","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,28]]}}}